4.7 Article

Temporal Dissection of Tumorigenesis in Primary Cancers

期刊

CANCER DISCOVERY
卷 1, 期 2, 页码 137-143

出版社

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/2159-8290.CD-11-0028

关键词

-

类别

资金

  1. Dermatology Foundation
  2. National Institute of Arthritis, Musculoskeletal, and Skin Diseases [K08AR057763]
  3. NIH/NCI [K08 CA137153, U24 CA1437991]
  4. University of California Cancer Coordinating Committee
  5. NIH/National Center for Research Resources/OD UCSF-Clinical & Translational Science Institute [KL2 RR024130]
  6. Canary Foundation/American Cancer Society
  7. Office of Science, Office of Biological and Environmental Research, U.S. Department of Energy [DE-AC02-05CH11231]
  8. NIH, National Cancer Institute (NCI) [P50 CA 58207, U54 CA 112970, NHGRI U24 CA 126551]
  9. Department of the Army (U.S. Army Medical Research Acquisition Activity, Fort Detrick, Maryland) [W81XWH-07-1-0663]
  10. Stand Up To Cancer-American Association for Cancer Research Dream Team Translational Cancer Research [SU2C-AACR-DT0409]
  11. Samsung Advanced Institute of Technology
  12. NIH [AR051930, R01AG028492]
  13. Medical Research Service, Department of Veterans Affairs
  14. NIH/National Institute of Arthritis and Musculoskeletal and Skin Diseases [5-P01-AR050440-05]
  15. Division Of Mathematical Sciences
  16. Direct For Mathematical & Physical Scien [1026441] Funding Source: National Science Foundation

向作者/读者索取更多资源

Timely intervention for cancer requires knowledge of its earliest genetic aberrations. Sequencing of tumors and their metastases reveals numerous abnormalities occurring late in progression. A means to temporally order aberrations in a single cancer, rather than inferring them from serially acquired samples, would define changes preceding even clinically evident disease. We integrate DNA sequence and copy number information to reconstruct the order of abnormalities as individual tumors evolve for 2 separate cancer types. We detect vast, unreported expansion of simple mutations sharply demarcated by recombinative loss of the second copy of TP53 in cutaneous squamous cell carcinomas (cSCC) and serous ovarian adenocarcinomas, in the former surpassing 50 mutations per megabase. In cSCCs, we also report diverse secondary mutations in known and novel oncogenic pathways, illustrating how such expanded mutagenesis directly promotes malignant progression. These results reframe paradigms in which TP53 mutation is required later, to bypass senescence induced by driver oncogenes. SIGNIFICANCE: Our approach reveals sequential ordering of oncogenic events in individual cancers, based on chromosomal rearrangements. Identifying the earliest abnormalities in cancer represents a critical step in timely diagnosis and deployment of targeted therapeutics. Cancer Discovery; 1(2); 137-43. (C) 2011 AACR.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据